SCHEMBL10244674

SCHEMBL10244674

CCCCc1ccc(C(=O)N[C@@H](CNC(=O)NS(=O)(=O)c2ccc(C)cc2)C(=O)N[C@@H](CC(C)C)B(O)O)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 8/20 0.45
LMNA P02545 2/20 0.44
ALDH1A1 P00352 1/20 0.44
ALB P02768 1/20 0.44
CYP2C9 P11712 1/20 0.44
TSHR P16473 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
PSMB1 P20618 2/20 0.41
PSMB2 P49721 2/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
CLPP Q16740 2/20 0.41
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
LONP1 P36776 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.39
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10246136 0.88 PSMB5 (0.53) PSMB5PSMB1PSMB2CLPPTAS1R3
SCHEMBL10243566 0.88 PSMB5 (0.53) PSMB5PSMB1PSMB2CLPPTAS1R3
SCHEMBL3164101 0.85 PSMB5 (0.49) PSMB5PSMB1PSMB2CLPPTAS1R3
SCHEMBL3155390 0.84 CA2 (0.50) PSMB5CA12CA1CA2CA9
SCHEMBL10245254 0.84 PSMB5 (0.52) PSMB5PSMB1PSMB2CLPPTAS1R3
SCHEMBL10243563 0.83 PSMB5 (0.47) PSMB5PSMB1PSMB2CLPPTAS1R3
SCHEMBL8295060 0.83 PSMB5 (0.54) PSMB5PSMB1PSMB2CLPPTAS1R3
SCHEMBL10244088 0.83 PSMB5 (0.54) PSMB5PSMB1PSMB2CLPPTAS1R3
SCHEMBL8295062 0.81 PSMB5 (0.53) PSMB5PSMB1PSMB2CLPPTAS1R3
SCHEMBL10243768 0.81 PSMB5 (0.63) PSMB5PSMB1PSMB2CLPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9233115-B2 Proteasome inhibitors and methods of using the same MILLENNIUM PHARMACEUTICALS INC. (US) 2016-01-12 US disclosed
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same CEPHALON, INC. (US) 2014-03-27 US disclosed
US-8546608-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2013-10-01 US disclosed
US-20120041196-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2012-02-16 US disclosed
US-8058262-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-11-15 US disclosed
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2011-06-16 US disclosed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US disclosed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US disclosed
US-7576206-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-08-18 US disclosed
US-7576206-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 PSMB5 2/4885LMNA 770/4885ALDH1A1 3935/4885
US-20120041196-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 PSMB5 2/4885LMNA 770/4885ALDH1A1 3935/4885
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same PSMB11, PSMB5, PSMB6 PSMB5 2/4885LMNA 770/4885ALDH1A1 3935/4885
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 PSMB5 2/4885LMNA 770/4885ALDH1A1 3935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.